Only a few patients have undergone an intensive gene therapy cure for sickle cell disease since it was approved by the FDA ...

A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β ...

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or prevent disease.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec ...

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look ...

Novartis reported that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) reached its primary endpoint in a Phase III study in paediatric patients aged two to 17 with type II ...

Astellas' aspirations in gene therapy have been knocked back by a series of setbacks, including cases of liver toxicity and deaths in a trial of its AT132 gene therapy candidate for rare disease X ...

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look ...

GT-0002X is under clinical development by Gene Therapy Research Institution and currently in Phase II for Parkinson's Disease.